person · Reporting owner

Haviland Kate

Disclosed activity across 4 companies

Tapewire entity: 32613
SEC CIK: 0001663022

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avalyn Pharma Inc.AVLN · Entity 4662	Director	April 29, 2026	May 01, 2026
Bicara Therapeutics Inc.BCAX · Entity 4673	Director	June 09, 2026	June 10, 2026
Fulcrum Therapeutics, Inc.FULC · Entity 5969	Director	June 30, 2026	July 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avalyn Pharma Inc.

Report date April 29, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-28	Direct	26,978	Reported balance After 2026-04-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-29 · Grant · Acquired 26,978 · Balance 26,978 F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Bicara Therapeutics Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2036-06-09	Direct	19,475	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 19,475 · Balance 19,475 F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Fulcrum Therapeutics, Inc.

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29	Direct	32,000	Reported balance After 2026-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-07-17 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2025-07-17 · Grant · Acquired 129,210 · Balance 295,139 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. Row 2 · 2025-07-17 · Disposition to issuer · Disposed 224,410 · Balance 70,729 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. Row 3 · 2025-07-17 · Other · Disposed 70,729 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.28	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 2 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.05	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 591 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.44	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 39,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 32,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 28,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 26,125 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31	Direct	Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.15	Direct	Reported balance After 2025-07-17 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.12	Direct	Reported balance After 2025-07-17 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.57	Direct	Reported balance After 2025-07-17 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-07-17 · Disposition to issuer · Disposed 70,400 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 13, 2021 Filed Dec 15, 2021 16:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,000	$36.05	$36,050.00	Disclosure SEC source: 0001179110-21-010988 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
September 13, 2021 Filed Sep 15, 2021 16:13 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	1,000	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-21-008782 · edgar.xml · derivative · entry 7 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,591 Underlying: Common Stock · 1,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the date hereof. Read SEC document
September 13, 2021 Filed Sep 15, 2021 16:13 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	8	$97.62	$780.96	Disclosure SEC source: 0001179110-21-008782 · edgar.xml · nonDerivative · entry 6 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.61 to $97.66 per share. Read SEC document
September 13, 2021 Filed Sep 15, 2021 16:13 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	28	$98.41	$2,755.48	Disclosure SEC source: 0001179110-21-008782 · edgar.xml · nonDerivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,956 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.735 to $98.67 per share. Read SEC document
September 13, 2021 Filed Sep 15, 2021 16:13 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	417	$99.25	$41,387.25	Disclosure SEC source: 0001179110-21-008782 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,984 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.70 to $99.67 per share. Read SEC document
September 13, 2021 Filed Sep 15, 2021 16:13 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	261	$99.98	$26,094.78	Disclosure SEC source: 0001179110-21-008782 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,401 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.70 to $100.67 per share. Read SEC document
September 13, 2021 Filed Sep 15, 2021 16:13 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	286	$101.11	$28,917.46	Disclosure SEC source: 0001179110-21-008782 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,662 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.71 to $101.69 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) in this form 4. Read SEC document
September 13, 2021 Filed Sep 15, 2021 16:13 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,000	$36.05	$36,050.00	Disclosure SEC source: 0001179110-21-008782 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
June 28, 2021 Filed Jun 30, 2021 16:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	1,000	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-21-007172 · edgar.xml · derivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 1,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
June 28, 2021 Filed Jun 30, 2021 16:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	24	$89.28	$2,142.72	Disclosure SEC source: 0001179110-21-007172 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.07 to $89.40 per share. Read SEC document
June 28, 2021 Filed Jun 30, 2021 16:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	622	$89.91	$55,924.02	Disclosure SEC source: 0001179110-21-007172 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,972 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.41 to $90.40 per share. Read SEC document
June 28, 2021 Filed Jun 30, 2021 16:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	354	$90.88	$32,171.52	Disclosure SEC source: 0001179110-21-007172 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,594 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.42 to $91.40 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) in this form 4. Read SEC document
June 28, 2021 Filed Jun 30, 2021 16:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,000	$36.05	$36,050.00	Disclosure SEC source: 0001179110-21-007172 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
June 09, 2021 Filed Jun 11, 2021 21:10 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $8.85	$0.00	Disclosure SEC source: 0000899243-21-023283 · doc4.xml · derivative · entry 1 Haviland Kate · CIK 0001663022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document
March 15, 2021 Filed Mar 17, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	1,000	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-21-003567 · edgar.xml · derivative · entry 7 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,591 Underlying: Common Stock · 1,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 15, 2021 Filed Mar 17, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	322	$104.65	$33,697.30	Disclosure SEC source: 0001179110-21-003567 · edgar.xml · nonDerivative · entry 6 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.04 to $105.03 per share. Read SEC document
March 15, 2021 Filed Mar 17, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	426	$105.44	$44,917.44	Disclosure SEC source: 0001179110-21-003567 · edgar.xml · nonDerivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,270 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.04 to $106.00 per share. Read SEC document
March 15, 2021 Filed Mar 17, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	108	$106.62	$11,514.96	Disclosure SEC source: 0001179110-21-003567 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,696 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.06 to $106.97 per share. Read SEC document
March 15, 2021 Filed Mar 17, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	138	$107.42	$14,823.96	Disclosure SEC source: 0001179110-21-003567 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,804 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.07 to $107.93 per share. Read SEC document
March 15, 2021 Filed Mar 17, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	6	$108.16	$648.96	Disclosure SEC source: 0001179110-21-003567 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,942 F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.11 to $108.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) in this form 4. Read SEC document
March 15, 2021 Filed Mar 17, 2021 17:48 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,000	$36.05	$36,050.00	Disclosure SEC source: 0001179110-21-003567 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:52 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,828	$86.61	$158,323.08	Disclosure SEC source: 0001179110-21-003011 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:52 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	124	$89.09	$11,047.16	Disclosure SEC source: 0001179110-21-003011 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,776 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.99 to $89.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 01, 2021 Filed Mar 3, 2021 16:30 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	26,125	$0.00 Strike: $100.13	$0.00	Disclosure SEC source: 0001179110-21-002677 · edgar.xml · derivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,125 Underlying: Common Stock · 26,125 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 01, 2021 Filed Mar 3, 2021 16:30 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	13,062	$0.00	$0.00	Disclosure SEC source: 0001179110-21-002677 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,900 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of a grant of 13,062 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	409	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-20-011198 · edgar.xml · derivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,591 Underlying: Common Stock · 409 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	409	$100.27	$41,010.43	Disclosure SEC source: 0001179110-20-011198 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,838 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100 to $100.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 16, 2020 Filed Nov 18, 2020 16:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	409	$36.05	$14,744.45	Disclosure SEC source: 0001179110-20-011198 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
October 16, 2020 Filed Oct 20, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	13,334	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-20-010601 · edgar.xml · derivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 13,334 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
October 16, 2020 Filed Oct 20, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	7,200	$100.55	$723,960.00	Disclosure SEC source: 0001179110-20-010601 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,838 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.24 to $101.235 per share. Read SEC document
October 16, 2020 Filed Oct 20, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	3,125	$101.56	$317,375.00	Disclosure SEC source: 0001179110-20-010601 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,038 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.24 per share. Read SEC document
October 16, 2020 Filed Oct 20, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	3,009	$102.53	$308,512.77	Disclosure SEC source: 0001179110-20-010601 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,163 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.40 to $102.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (4) of this form 4. Read SEC document
October 16, 2020 Filed Oct 20, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	13,334	$36.05	$480,690.70	Disclosure SEC source: 0001179110-20-010601 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
September 22, 2020 Filed Sep 24, 2020 16:19 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	3,143	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-20-009929 · edgar.xml · derivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 3,143 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on February 1, 2016. This option is fully vested as of the date hereof. Read SEC document
September 22, 2020 Filed Sep 24, 2020 16:19 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	3,143	$85.49	$268,695.07	Disclosure SEC source: 0001179110-20-009929 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,838 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.32 to $85.84 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
September 22, 2020 Filed Sep 24, 2020 16:19 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	3,143	$16.28	$51,168.04	Disclosure SEC source: 0001179110-20-009929 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
June 11, 2020 Filed Jun 15, 2020 20:15 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	GrantStock Option (right to buy) · Derivative	9,285	$0.00 Strike: $17.63	$0.00	Disclosure SEC source: 0000899243-20-016496 · doc4.xml · derivative · entry 1 Haviland Kate · CIK 0001663022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,285 Underlying: Common Stock · 9,285 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document
March 09, 2020 Filed Mar 11, 2020 16:29 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	671	$51.98	$34,878.58	Disclosure SEC source: 0001179110-20-003473 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,838 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document
March 03, 2020 Filed Mar 3, 2020 19:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	4,644	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-20-002966 · edgar.xml · derivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,145 Underlying: Common Stock · 4,644 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 03, 2020 Filed Mar 3, 2020 19:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	4,644	$16.28	$75,604.32	Disclosure SEC source: 0001179110-20-002966 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2020 Filed Mar 3, 2020 19:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	28,500	$0.00 Strike: $54.13	$0.00	Disclosure SEC source: 0001179110-20-002966 · edgar.xml · derivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2030-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 01, 2020 Filed Mar 3, 2020 19:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	14,250	$0.00	$0.00	Disclosure SEC source: 0001179110-20-002966 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,865 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of a grant of 14,250 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 14,250 newly awarded restricted stock units, 8,750 previously reported restricted stock units, 2,188 of which vested on March 1, 2020, and 15,865 shares of common stock. Read SEC document
January 10, 2020 Filed Jan 14, 2020 16:47 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	7,763	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-20-000551 · edgar.xml · derivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,789 Underlying: Common Stock · 7,763 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
January 10, 2020 Filed Jan 14, 2020 16:47 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	7,763	$85.16	$661,097.08	Disclosure SEC source: 0001179110-20-000551 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,865 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.40 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
January 10, 2020 Filed Jan 14, 2020 16:47 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	7,763	$16.28	$126,381.64	Disclosure SEC source: 0001179110-20-000551 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
August 19, 2019 Filed Aug 21, 2019 16:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	95	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-19-009747 · edgar.xml · derivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,552 Underlying: Common Stock · 95 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
August 19, 2019 Filed Aug 21, 2019 16:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	95	$85.00	$8,075.00	Disclosure SEC source: 0001179110-19-009747 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,865 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
August 19, 2019 Filed Aug 21, 2019 16:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	95	$16.28	$1,546.60	Disclosure SEC source: 0001179110-19-009747 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
July 18, 2019 Filed Jul 18, 2019 21:27 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	GrantStock Option (right to buy) · Derivative	9,285	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001104659-19-040969 · a4.xml · derivative · entry 1 Haviland Kate · CIK 0001663022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,285 Underlying: Common Stock · 9,285 shares Expires 2029-07-17 F1 · derivative.exercise_date: The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest on July 18, 2020 or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document
July 16, 2019 Filed Jul 18, 2019 19:53 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	11,562	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-19-008727 · edgar.xml · derivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,647 Underlying: Common Stock · 11,562 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Consists of (i) exercise to acquire 1,571 shares effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and (ii) a separate cash exercise to acquire 9,991 shares. F5 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.